Epidemiologic studies have previously suggested that premenopausal females have
reduced incidence of cardiovascular disease (CVD) when compared to age-matched males …

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

Background: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention
with β-blockers remains controversial. Objectives: This prospective, randomized, double …

Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Current therapy of advanced cancers is based on several modalities including radiotherapy,
cytotoxic chemotherapy, molecularly targeted inhibitors and antibodies targeting immune …

Cardiovascular disease and cancer are the leading causes of death in the United States,
and hormone-dependent cancers (breast and prostate cancer) are the most common …

Background: The association between aromatase inhibitors and cardiovascular outcomes
among women with breast cancer is controversial. Given the discrepant findings from …

Background A number of randomized controlled trials (RCTs) have reported improvement in
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …

Background There is growing evidence that breast cancer survivors have higher
cardiovascular disease (CVD) mortality relative to the general population. Information on …

Objective To investigate the effect of endocrine therapies on a wide range of specific clinical
cardiovascular disease outcomes in women with a history of non-metastatic breast cancer …